Biogen shares plunge after it scraps Alzheimer’s treatment

Shares of Biogen tanked on Thursday after it announced its ending late-stage trials for a experimental Alzheimer’s drug. Yahoo Finance's Scott Gamm caught up with Sarge986 LLC President Stephen Guilfoyle to discuss the news.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting